Previous 10 | Next 10 |
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of A...
2023-07-18 11:32:07 ET Shares of Acumen Pharmaceuticals (NASDAQ: ABOS) were down more than 16% at 11 a.m. on Tuesday after the company announced a public stock offering. The company's shares are still up more than 50% so far this year. The clinical-stage biotech company focu...
2023-07-18 08:34:40 ET Summary Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market for Alzheimer's disease treatments is expected to rise past $13 billion by 2030. There was statist...
2023-07-17 17:27:38 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ) has proposed an underwritten public offering of its common stock to raise $100 million, the company said Monday. All of the shares to be sold in the offering are to be sold by the company. The underwr...
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s dis...
2023-07-17 10:07:51 ET Gainers: ProMIS Neurosciences ( PMN ) +149% . BridgeBio Pharma ( BBIO ) +62% . Acumen Pharmaceuticals ( ABOS ) +60% . Healthcare Triangle ( HCTI ) +42% . argenx ( ARGX ) +30% . Losers: Apellis P...
2023-07-17 10:00:46 ET Shares of Acumen Pharmaceuticals ( NASDAQ: ABOS ) rallied more than 60% in early trading Monday in the wake of the release of positive data from a Phase 1 clinical trial for its Alzheimer's disease drug candidate ACU193. Acumen shares opened at a $6.11, re...
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s dis...
Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody Rapid, dose-related, statistically significant (p=0.01) amyloid plaque reduction ob...
2023-07-13 08:03:58 ET Summary Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique binding profile. Results of the ...
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer’s disease (AD),&...
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...